GILD
GILEAD SCIENCES, INC.Company Information
- Company Name
- GILEAD SCIENCES, INC.
- CIK
- CIK0000882095
- Category
- Large accelerated filer
- Ticker: Exchange
- GILD: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- GILD
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-06-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 602,731
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 973,233,293
- Shares outstanding
- 1,242,000,000
- Ownership
- 78.36%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 11.33%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3,179 | 7,628 | 7,564 | 7,330 | 5,144 | 7,926 | 9,991 | 5,037 | 2,772 | 4,718 | 6,085 | 5,705 | ||||||
| Marketable Securities Current | 0 | 15 | 68 | 19 | 69 | - | 0 | 0 | 0 | 0 | 1,179 | 1,159 | ||||||
| Accounts Receivable Net Current | 5,055 | 4,741 | 4,913 | 5,095 | 4,781 | 4,388 | 4,420 | 4,587 | 4,663 | 4,669 | 4,660 | 4,790 | ||||||
| Inventory Net | 1,953 | 1,914 | 1,774 | 1,785 | 1,825 | 1,759 | 1,710 | 1,869 | 2,026 | 1,853 | 1,787 | 1,663 | ||||||
| Prepaid Expense And Other Assets Current | 3,759 | 4,342 | 4,024 | 3,645 | 2,899 | 2,828 | 3,052 | 3,287 | 2,856 | 2,800 | 2,374 | 2,662 | ||||||
| Assets Current | 13,945 | 18,641 | 18,342 | 17,874 | 14,718 | 16,901 | 19,173 | 14,779 | 12,317 | 14,041 | 16,085 | 15,980 | ||||||
| Property Plant And Equipment Net | 5,833 | 5,638 | 5,606 | 5,500 | 5,459 | 5,421 | 5,414 | 5,391 | 5,346 | 5,321 | 5,317 | 5,572 | ||||||
| Marketable Securities Noncurrent | 0 | 983 | 2,974 | 2,005 | 1,913 | - | 0 | 0 | 0 | 0 | 1,163 | 1,156 | ||||||
| Intangible Assets Net Excluding Goodwill | 14,032 | 16,382 | 16,978 | 17,970 | 18,566 | 19,355 | 19,948 | 20,546 | 22,832 | 23,428 | 26,454 | 27,152 | ||||||
| Goodwill | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | 8,314 | ||||||
| Deferred Income Tax Assets Net | 2,487 | 1,767 | 1,964 | 1,998 | 2,721 | 2,572 | 2,378 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 4,751 | 4,554 | 4,845 | 4,873 | 4,031 | 3,871 | 3,769 | 5,494 | 4,770 | 5,188 | 4,792 | 4,200 | ||||||
| Assets | 49,362 | 56,278 | 59,023 | 58,533 | 55,721 | 56,434 | 58,995 | 54,525 | 53,579 | 56,292 | 62,125 | 62,373 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 674 | 645 | 715 | 808 | 582 | 737 | 833 | 903 | 537 | 622 | 550 | 586 | ||||||
| Debt Current | 2,414 | 1,313 | 2,807 | 2,806 | 2,806 | 2,806 | 1,815 | 1,812 | 1,810 | 3,667 | 1,798 | 1,793 | ||||||
| Other Liabilities Current | 3,699 | 3,399 | 3,953 | 3,752 | 3,586 | 4,615 | 5,464 | 4,896 | 4,510 | 4,464 | 5,130 | 5,852 | ||||||
| Liabilities Current | 11,020 | 9,476 | 11,813 | 12,298 | 11,189 | 12,344 | 12,004 | 11,725 | 10,781 | 13,015 | 11,280 | 11,945 | ||||||
| Long Term Debt Noncurrent | 23,832 | 20,861 | 22,129 | 22,135 | 22,140 | 22,146 | 24,896 | 21,437 | 21,540 | 21,527 | 23,189 | 23,189 | ||||||
| Accrued Income Taxes Noncurrent | 943 | 918 | 896 | 866 | 859 | 819 | 830 | 782 | 738 | 1,967 | 2,039 | 2,088 | ||||||
| Deferred Income Tax Liabilities Net | 333 | 392 | 402 | 597 | 652 | 709 | 724 | 794 | 907 | 933 | 1,588 | 1,984 | ||||||
| Other Liabilities Noncurrent | 1,490 | 1,200 | 1,165 | 1,182 | 1,290 | 1,337 | 1,295 | 1,396 | 1,418 | 1,395 | 1,280 | 924 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 9,532 | 9,305 | 8,932 | 8,678 | 8,367 | 8,138 | 7,700 | 7,327 | 7,022 | 6,813 | 6,500 | 6,279 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 95 | 78 | 39 | 36 | -18 | 92 | 132 | 73 | 93 | 69 | 28 | 31 | ||||||
| Retained Earnings Accumulated Deficit | 2,200 | 14,131 | 13,730 | 12,825 | 11,325 | 10,931 | 11,497 | 11,073 | 11,165 | 10,656 | 16,304 | 16,002 | ||||||
| Stockholders Equity | 11,744 | 23,431 | 22,703 | 21,456 | 19,590 | 19,078 | 19,330 | 18,475 | 18,197 | 17,455 | 22,749 | 22,314 | ||||||
| Minority Interest | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -84 | -72 | ||||||
| Liabilities And Stockholders Equity | 49,362 | 56,278 | 59,023 | 58,533 | 55,721 | 56,434 | 58,995 | 54,525 | 53,579 | 56,292 | 62,125 | 62,373 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | 5,600 | ||||||
| Common Stock Shares Issued | 1,241 | 1,242 | 1,241 | 1,242 | 1,242 | 1,245 | 1,246 | 1,246 | 1,246 | 1,246 | 1,246 | 1,247 | ||||||
| Shares Outstanding | 1,241 | 1,242 | 1,241 | 1,242 | 1,242 | 1,245 | 1,246 | 1,246 | 1,246 | 1,246 | 1,246 | 1,247 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGILEAD SCIENCES, INC. (GILD) — SEC Financial Statements & Analysis
GILEAD SCIENCES, INC. (GILD) is a biological products, (no diagnostic substances) company, incorporated in DE. GILEAD SCIENCES, INC. trades on Nasdaq as: GILD. GILEAD SCIENCES, INC. (GILD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, GILEAD SCIENCES, INC. carries a market cap of $157.04B, a P/E ratio of -48.47x, a P/B ratio of 13.37x, a P/S ratio of 5.16x, an enterprise value of $180.11B, and an EV/EBITDA multiple of -84.72x. On profitability, it posts a gross margin of 79.59%, an operating margin of -8.20%, a net margin of -10.64%, a Return on Equity (ROE) of -20.68%, a Return on Assets (ROA) of -6.17%, and a Return on Invested Capital (ROIC) of -6.62%. Per share, it reports EPS of $-2.61, diluted EPS of $-2.61, free cash flow per share of $10.41, and a dividend per share of $3.27. Over the trailing year, it posted revenue growth of 5.52% year-over-year, net income growth of -151.34% year-over-year, and EPS growth of -151.42% year-over-year. On the balance sheet, it maintains a current ratio of 1.27x, a quick ratio of 0.75x, working capital of $2.92B, a debt-to-equity ratio of 0.94x, a debt ratio of 0.22, an interest coverage ratio of -2.50x, free cash flow of $12.94B (TTM), and net debt of $23.07B. Figures sourced from SEC EDGAR.
- Market Cap
- $157.04B
- P/E TTM
- -48.47x
- EPS TTM
- $-2.61
- P/B TTM
- 13.37x
- ROE TTM
- -20.68%
- ROA TTM
- -6.17%
- Debt To Equity
- 0.94x
- Free Cash Flow TTM
- $12.94B
- Net Revenue TTM Growth 1Y
- 5.52%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GILEAD SCIENCES, INC. in?
GILEAD SCIENCES, INC. (GILD) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does GILD trade on?
GILEAD SCIENCES, INC. (GILD) trades on the Nasdaq.
Where is GILEAD SCIENCES, INC. incorporated?
GILEAD SCIENCES, INC. is incorporated in DE.
When was GILEAD SCIENCES, INC. (GILD)'s most recent SEC filing?
GILEAD SCIENCES, INC. (GILD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is GILD's market cap?
GILEAD SCIENCES, INC. (GILD) has a market capitalization of $157.04B as of 2026-06-30.
What is GILD's EPS (earnings per share)?
GILEAD SCIENCES, INC. (GILD)'s trailing twelve month EPS is $-2.61 as of 2026-06-30.
What is GILD's ROE (return on equity)?
GILEAD SCIENCES, INC. (GILD)'s trailing twelve month Return on Equity (ROE) is -20.68% as of 2026-06-30.
What is GILD's ROA (return on assets)?
GILEAD SCIENCES, INC. (GILD)'s trailing twelve month Return on Assets (ROA) is -6.17% as of 2026-06-30.
What is GILD's ROIC (return on invested capital)?
GILEAD SCIENCES, INC. (GILD)'s trailing twelve month Return on Invested Capital (ROIC) is -6.62% as of 2026-06-30.
What is GILD's EV/EBITDA?
GILEAD SCIENCES, INC. (GILD)'s trailing twelve month EV/EBITDA is -84.72x as of 2026-06-30.